Prognostic Model of Elderly Hodgkin Lymphoma in China

N/AActive Not RecruitingNCT07374068

Tianjin Medical University Cancer Institute and Hospital400 enrolled

Overview

This multicenter observational cohort study is based on a patient registry designed to systematically collect uniform real-world clinical data from elderly patients with Hodgkin lymphoma (HL) in China. The registry captures demographic characteristics, disease features, laboratory parameters, treatment patterns, and longitudinal survival outcomes to support predefined scientific objectives. The primary analysis uses retrospectively collected registry data, with prospectively accrued data incorporated for external validation of a prognostic prediction model. This registry-based study aims to improve risk stratification and inform individualized clinical decision-making for elderly patients with HL in routine clinical practice.

Study Type

OBSERVATIONAL

Enrollment

400

Conditions

Hodgkin Lymphoma

Eligibility

Sex: ALLMin age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥60 years * Histologically confirmed Hodgkin lymphoma, including classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma * Treatment-naïve patients who have not received prior anti-Hodgkin lymphoma therapy * Availability of complete clinical, pathological, and follow-up data Exclusion Criteria: * Presence of other malignant tumors * Severe hepatic or renal dysfunction (Child-Pugh class C or estimated glomerular filtration rate \<30 mL/min) * Missing more than 20% of required clinical data

Locations (1)

Outcomes

Primary Outcomes

Overall Survival (OS)

Overall survival (OS) is defined as the time from diagnosis to death from any cause.

Time frame: From date of diagnosis until death from any cause, assessed up to 60 months.

Secondary Outcomes

Progression-Free Survival (PFS)

Progression-free survival (PFS) is defined as the time from diagnosis to disease progression or death from any cause.

Time frame: From date of diagnosis until the date of first documented disease progression or death from any cause, whichever occurs first, assessed up to 60 months.

Disease-Free Survival (DFS)

Disease-free survival (DFS) is defined as the time from remission to disease relapse or death from any cause.

Time frame: From date of first documented remission until disease relapse or death from any cause, whichever occurs first, assessed up to 60 months.

Event-Free Survival (EFS)

Event-free survival (EFS) is defined as the time from diagnosis to treatment failure, disease relapse, or death from any cause.

Time frame: From date of diagnosis until treatment failure, disease relapse, or death from any cause, whichever occurs first, assessed up to 60 months.

Proportion of Participants With Disease Progression or Death Within 24 Months From Diagnosis (POD24)

Progression of disease within 24 months (POD24) is defined as the occurrence of documented disease progression or death from any cause within 24 months from the date of diagnosis.

Time frame: From date of diagnosis to 24 months after diagnosis.